



#4A MDT B
J. Scott
#-8-02
CASE 4-30096B/C1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 041586024 US
Express Mail Label Number

1/8/02
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

ZIMMERMANN ET AL.

Examiner: Emily Bernhardt

APPLICATION NO: 09/991,184

FILED: NOVEMBER 16, 2001

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS
USE

RECEIVED

JAN 17 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

SECOND PRELIMINARY AMENDMENT

Sir:

Prior to consideration of the above-identified application, Applicants request that the following amendments be entered.

IN THE CLAIMS:

Please delete claims 13-15.

Please add the following claims:

16. A method of preventing or treating restenosis comprising administering a therapeutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide to a warm-blooded animal, wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide is present in free form or in pharmaceutically acceptable salt form.

17. A method of preventing or treating atherosclerosis comprising administering a therapeutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide to a warm-blooded animal, wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide is present in free form or in pharmaceutically acceptable salt form.

01/16/2002 MWOLDER1 00000077 190134 09991184

01 FC:102
02 FC:103

1176.00 CH
144.00 CH